These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29043234)

  • 1. Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma.
    Kim HY; Jang MA; Kim HJ; Kim SJ; Kim WS; Kim SH
    Blood Res; 2017 Sep; 52(3):193-199. PubMed ID: 29043234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
    Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China.
    Yin T; Qi L; Zhou Y; Kong F; Wang S; Yu M; Li F
    J Int Med Res; 2022 Sep; 50(9):3000605221110075. PubMed ID: 36112929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean.
    Kong SY; Cho EH; Woo HY; Park Q; Ko YH; Kim SH
    J Korean Med Sci; 2004 Dec; 19(6):815-9. PubMed ID: 15608391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma].
    Fan Y; Dong L; OUYang BS; Xu HM; Zheng SF; Wang AR; Wang CF
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):448-453. PubMed ID: 32392928
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
    Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
    Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
    Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
    Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
    Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
    Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
    Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
    Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
    Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
    Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
    Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
    Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.
    Fan Y; Binshen O; Zhang Z; Yi H; Zhang W; Liu Q; Liu Y; Dong L; Wang C
    Ann Diagn Pathol; 2022 Jun; 58():151886. PubMed ID: 35255429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes.
    Xia Y; Ge J; Sun Z; Nan F; Wan W; Xu D; Zhang M; Fu X
    Leuk Res; 2022 Jun; 117():106840. PubMed ID: 35468520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.
    Ma D; Ma Y; Ma Y; Liu J; Gu Y; Liu N; Xiang C; Liu H; Sang W
    Front Oncol; 2022; 12():941347. PubMed ID: 36081566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients.
    Huang H; Li Z; Huang C; Rao J; Xie Q; Cui W; Tou F; Zheng Z
    Open Med (Wars); 2018; 13():605-609. PubMed ID: 30519638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma.
    Yang M; Niu X; Yang X; Sun Y; Su W; Zhang J; Wu Q; Wang Y; Zhang Q; Ji H
    Exp Biol Med (Maywood); 2023 Sep; 248(17):1469-1478. PubMed ID: 36847415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
    Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
    Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of bone marrow involvement by immunoglobulin gene rearrangement in
    Kim YR; Shin HJ; Yhim HY; Yang DH; Park Y; Lee JH; Lee WS; Do YR; Mun YC; Kim DS; Kim JS
    Front Oncol; 2024; 14():1363385. PubMed ID: 38410112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.